Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001244319 | SCV001417531 | uncertain significance | not provided | 2021-09-01 | criteria provided, single submitter | clinical testing | This sequence change replaces valine with isoleucine at codon 248 of the GRHPR protein (p.Val248Ile). The valine residue is highly conserved and there is a small physicochemical difference between valine and isoleucine. This variant is present in population databases (rs369950120, ExAC 0.01%). This variant has not been reported in the literature in individuals affected with GRHPR-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV001829926 | SCV002790542 | uncertain significance | Primary hyperoxaluria, type II | 2021-12-08 | criteria provided, single submitter | clinical testing | |
Clinical Biochemistry Laboratory, |
RCV001829926 | SCV004174330 | likely pathogenic | Primary hyperoxaluria, type II | 2023-10-27 | criteria provided, single submitter | curation | Another mutation (c.743T>A), affecting the same amino acid, has been found in a patient with PH2. ACMG: PM1 PM2 PM5 'Likely pathogenic' |
Natera, |
RCV001829926 | SCV002075688 | uncertain significance | Primary hyperoxaluria, type II | 2020-02-26 | no assertion criteria provided | clinical testing |